Synaptic vesicular amine transporter — Drug Target

All drugs that target Synaptic vesicular amine transporter — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

rescinnamine · Catecholamine-depleting Sympatholytic · Vesicular Monoamine Transporter 2 Inhibitor [EPC]

Marketed (4)

• Austedo · Teva · Metabolic
  Austedo works by binding to the synaptic vesicular amine transporter, reducing the release of dopamine and other neurotransmitters.
• Moderil · Pfizer · rescinnamine · Neuroscience
• Raunormin · Catecholamine-depleting Sympatholytic · Cardiovascular
• Xenazine · Bausch Health · Vesicular Monoamine Transporter 2 Inhibitor [EPC] · Metabolic
  Xenazine works by blocking the reuptake of dopamine and other neurotransmitters into synaptic vesicles, reducing their release and alleviating symptoms of Huntington's chorea.